Literature DB >> 20969854

Activation of α7 nicotinic acetylcholine receptors ameliorates indomethacin-induced small intestinal ulceration in mice.

Ryoji Kawahara1, Masashi Yasuda, Hiroshi Hashimura, Kikuko Amagase, Shinichi Kato, Koji Takeuchi.   

Abstract

Cholinergic anti-inflammatory actions have been shown to result mainly from the activation of α7 nicotinic acetylcholine receptors. Here, we investigated the possible role of α7 nicotinic acetylcholine receptors in the pathogenesis of indomethacin-induced small intestinal ulceration in mice. Male C57BL/6 mice were given indomethacin (10mg/kg, s.c.), and sacrificed 24h later. Nicotine (0.3-3mg/kg) and PNU-282987 (a selective agonist of α7 nicotinic acetylcholine receptors; 1-10mg/kg) were administered i.p. twice, at 0.5h before and 8h after indomethacin treatment, while methyllycaconitine (a selective antagonist of α7 nicotinic acetylcholine receptors; 10mg/kg was administered twice, at 0.5h before each nicotine treatment. Indomethacin caused severe hemorrhagic lesions in the small intestine with marked increases in myeloperoxidase (MPO) activity and inducible nitric oxide synthase (iNOS) expression in the mucosa. Pretreatment with nicotine reduced the severity of intestinal lesions in a dose-dependent manner. The protective effect of nicotine was mimicked by PNU-282987 and significantly attenuated by methyllycaconitine. The increases in MPO activity and iNOS expression induced by indomethacin were also significantly suppressed by nicotine and PNU-282987. Immunohistochemical study showed that the expression of α7 nicotinic acetylcholine receptors was clearly enhanced in the submucosa of the damaged area following indomethacin treatment. These results suggest that the activation of α7 nicotinic acetylcholine receptors ameliorates indomethacin-induced small intestinal ulceration, and that this effect may result from the inhibition of iNOS expression and neutrophil migration.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20969854     DOI: 10.1016/j.ejphar.2010.10.031

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy.

Authors:  John L Wallace
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

2.  The microglial α7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2.

Authors:  Esther Parada; Javier Egea; Izaskun Buendia; Pilar Negredo; Ana C Cunha; Silvia Cardoso; Miguel P Soares; Manuela G López
Journal:  Antioxid Redox Signal       Date:  2013-02-25       Impact factor: 8.401

3.  Novel insights on the effect of nicotine in a murine colitis model.

Authors:  Shakir D AlSharari; Hamid I Akbarali; Rehab A Abdullah; Omer Shahab; Wimolnut Auttachoat; Gabriela A Ferreira; Kimber L White; Aron H Lichtman; Guy A Cabral; M Imad Damaj
Journal:  J Pharmacol Exp Ther       Date:  2012-10-31       Impact factor: 4.030

4.  Preventative Effects of Sodium Alginate on Indomethacin-induced Small-intestinal Injury in Mice.

Authors:  Sayo Horibe; Toshihito Tanahashi; Shoji Kawauchi; Shigeto Mizuno; Yoshiyuki Rikitake
Journal:  Int J Med Sci       Date:  2016-08-01       Impact factor: 3.738

Review 5.  Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects.

Authors:  Wenji Zhang; Hui Lin; Mingmin Zou; Qinghua Yuan; Zhenrui Huang; Xiaoying Pan; Wenjuan Zhang
Journal:  Front Immunol       Date:  2022-02-18       Impact factor: 7.561

6.  Exclusive enteral nutrition protects against inflammatory bowel disease by inhibiting NF‑κB activation through regulation of the p38/MSK1 pathway.

Authors:  Ting Yu; Qian Yu; Xiaotian Chen; Lixing Zhou; Yuming Wang; Chenggong Yu
Journal:  Int J Mol Med       Date:  2018-06-04       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.